We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$61.5B
1-Year Est. Return
30.7%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+30.7%
3 Year Est. Return
+96.89%
5 Year Est. Return
+121.97%
10 Year Est. Return
+542.41%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.21% |
| 2 | Technology | 14.44% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 8.99% |
| 5 | Consumer Discretionary | 8.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Gilead Sciences
GILD
$165B
| $277M | 0.69% |
3,590,631
-2,050,261
| -36% | -$164M |
|
27
Trane Technologies
TT
$99.6B
| $266M | 0.66% |
1,389,558
+208,221
| +18% | +$37M |
|
|
PPL
28
PPL Corp
PPL
$27.4B
| $264M | 0.66% |
9,983,981
-66,927
| -0.7% | -$1.85M |
|
29
TotalEnergies
TTE
$192B
| $256M | 0.63% |
4,435,641
-30,718
| -0.7% | -$1.86M |
|
30
Conagra Brands
CAG
$7.45B
| $254M | 0.63% |
7,539,055
-1,494,129
| -17% | -$53.9M |
|
31
AbbVie
ABBV
$471B
| $248M | 0.62% |
1,842,318
-784,659
| -30% | -$115M |
|
32
Medtronic
MDT
$113B
| $244M | 0.6% |
2,764,161
+29,089
| +1% | +$2.5M |
|
33
Entergy
ETR
$51.4B
| $236M | 0.59% |
4,840,600
+43,052
| +0.9% | +$2.23M |
|
34
Visa
V
$703B
| $235M | 0.58% |
989,397
+153,773
| +18% | +$35.2M |
|
35
Coca-Cola
KO
$389B
| $227M | 0.56% |
3,762,987
+368,973
| +11% | +$23M |
|
36
Costco
COST
$432B
| $224M | 0.56% |
416,517
-6,642
| -2% | -$3.36M |
|
37
Crown Castle
CCI
$33.7B
| $215M | 0.53% |
1,888,592
-44,152
| -2% | -$5.26M |
|
38
Enbridge
ENB
$121B
| $214M | 0.53% |
5,765,981
+28,043
| +0.5% | +$1.07M |
|
39
BCE
BCE
$20.5B
| $214M | 0.53% |
4,684,610
+43,332
| +0.9% | +$2.02M |
|
40
Baidu
BIDU
$35.4B
| $213M | 0.53% |
1,556,013
+508,857
| +49% | +$66.6M |
|
41
NVIDIA
NVDA
$4.64T
| $203M | 0.5% |
4,800,070
+422,800
| +10% | +$14M |
|
42
Wingstop
WING
$3.95B
| $201M | 0.5% |
1,002,076
+19,828
| +2% | +$3.87M |
|
43
CoStar Group
CSGP
$11.9B
| $198M | 0.49% |
2,222,392
-375,763
| -14% | -$29M |
|
44
Amphastar Pharmaceuticals
AMPH
$899M
| $197M | 0.49% |
3,428,930
+42,317
| +1% | +$1.88M |
|
45
Eli Lilly
LLY
$1.09T
| $196M | 0.49% |
418,506
+30,899
| +8% | +$13M |
|
46
National Grid
NGG
$79.9B
| $193M | 0.48% |
3,047,818
+312,722
| +11% | +$20.5M |
|
47
Danaher
DHR
$142B
| $168M | 0.42% |
790,093
-30,788
| -4% | -$6.52M |
|
|
DVAX
48
DELISTED
Dynavax Technologies
DVAX
| $164M | 0.41% |
12,655,363
| – | – |
|
49
TJX Companies
TJX
$179B
| $162M | 0.4% |
1,916,164
-17,551
| -0.9% | -$1.38M |
|
50
TC Energy
TRP
$70.7B
| $159M | 0.4% |
3,942,447
+676,688
| +21% | +$27.6M |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.